NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Neucore Bio

Neucore Bio

Private
SingaporeHealthcare & Life Scienceshttps://neucorebio.com/

Last Round

Grant

Sep 2, 2025

Total Funding Raised

$4.7M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Neucore Bio is a biotechnology company developing a pipeline of first-in-class antibody-based therapeutics to treat neurodegenerative diseases like Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD).

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

engineered exosomesnon-viral gene deliverygene therapy deliveryextracellular vesiclesdrug delivery platformplatform biotechAAV alternativegenetic medicinefibroblast-derived exosomesneurological disease therapytherapeutic deliveryredosinglow immunogenicitySmall Business Technology TransferSTTR

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Neucore Bio Comps

Public and private peers based on sector, stage, and business model.

Neucore Bio comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Neucore Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantSep 2, 2025
GrantAug 6, 2025
SeedFeb 6, 2024
GrantJul 11, 2023

Key People

Founding team and executive leadership

Kenny Morand

Co-Founder, Chief Executive Officer

Founding Team

Brian Price

Chief Technology Officer

Executive Team

Neucore Bio Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 17, 2026

    Monthly visitors grew 210% MoM, from 287 to 889.

  • Jan 6, 2026

    Monthly visitors grew 71% MoM.

Neucore Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Neucore Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Neucore Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersSingapore
Employee Range6
Year Founded2022
Last FundingSep 2, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.